Clinical trials: Pegfilgrastim
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
This phase I/II trial is studying the side effects and best dose of oblimersen when given together with rituximab and combination chemotherapy and to see how well they work in treating patients with relapsed or refractory…
- Conditions
- Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
- Trial name
- NCT00086944
- Testing
- oblimersen sodium, rituximab, ifosfamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants).
- Conditions
- Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
- Trial name
- NCT04383743
- Testing
- Cisplatin, Doxorubicin, Methotrexate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
Non-Small Cell Lung Cancer
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
The primary objective of Part I of the study is to determine tumor response rate of sequential topoisomerase targeting with irinotecan/oxaliplatin followed by etoposide /carboplatin in chemotherapy-naïve patients with extensive…
- Trial name
- NCT00240097
- Testing
- Intervention A: Irinotecan; Oxaliplatin; Neulasta, Intervention B: Etoposide; Carboplatin; Neulasta
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Alabama at Birmingham
Fallopian Tube Cancer, Ovarian Cancer
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and trabectedin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00569673
- Testing
- filgrastim, pegfilgrastim, docetaxel
- Where
- 37 sites in United States
- Volunteers
- 71 people
- Sponsor
- Gynecologic Oncology Group
Breast Cancer, Stage I Breast Cancer
Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer
The main purpose of this study is to see if pegfilgrastim (Neulasta) is safe and useful in supporting people through dose-dense chemotherapy, and to see if a long-acting red blood cell growth factor, darbepoetin alfa(Aranesp) can…
- Conditions
- Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT00146562
- Testing
- Darbepoetin Alfa, Pegfilgrastim, Paclitaxel
- Where
- 6 sites in United States
- Volunteers
- 135 people
- Sponsor
- Harold J. Burstein, MD, PhD
Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, ifosfamide, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor
- Trial name
- GemTIP (NCT00551122)
- Testing
- filgrastim, lenograstim, pegfilgrastim
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- University of Southampton
Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers
Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
The study was an assessor-blind, balanced, randomized, two-treatment, two-period, single-dose, two-way crossover, comparative, pharmacokinetic (PK) and pharmacodynamic (PD) study of subcutaneous (SC) Pegfilgrastim injection (6…
- Trial name
- NCT04014062
- Testing
- INTP5, US Neulasta
- Where
- India
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Intas Pharmaceuticals, Ltd.
Myeloid Leukemia
Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
The purpose of this study is to determine if a single dose of pegfilgrastim is able to reduce the time of severe neutropenia in patients receiving induction and consolidation myelosuppressive chemotherapy for de novo acute…
- Trial name
- NCT00114764
- Testing
- filgrastim, pegfilgrastim
- Volunteers
- 84 people
- Sponsor
- Amgen
Pancreatic Ductal Adenocarcinoma
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
The purpose of this study is to combine standard radiation therapy with drugs that encourages the body's immune system against cancer cells and simultaneously adding drugs which also target the pathway that the tumor uses to…
- Trial name
- AIRPanc (NCT06048484)
- Testing
- Stereotactic body radiotherapy (SBRT), Zimberelimab, Quemliclustat
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Gulam Manji
Locally Advanced Pancreatic Cancer, Pancreatic Cancer
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10…
- Trial name
- NCT02578732
- Testing
- FOLFOXA
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Brown University
Breast Cancer
Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer
In this trial we will evaluate ABI-007 with gemcitabine and epirubicin, utilizing the biweekly pegfilgrastim support, in order to further improve upon the effectiveness and favorable toxicity of this triplet.
- Trial name
- NCT00193206
- Testing
- Gemcitabine, Epirubicin, Albumin-bound Paclitaxel
- Where
- 13 sites in United States
- Volunteers
- 123 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080626
- Testing
- pegfilgrastim, docetaxel, conventional surgery
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HIV Infections, Diffuse Large B Cell Lymphoma
LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)
Main objective: To evaluate the applicability of the treatment: 1. To evaluate the treatment toxicity according to the Common Terminology Criteria (CTC) version 3.0 of the National Cancer Institute (NCI). 2.
- Trial name
- LINFOTARGAM (NCT00466258)
- Testing
- R-CHOP, Highly active antiretroviral therapy, Central nervous system (CNS) prophylaxis
- Where
- 15 sites in Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Multiple Myeloma
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
The purpose of this study is to compare the effects, good and bad, of two ways to treat patients with standard-risk symptomatic multiple myeloma.
- Trial name
- NCT00807599
- Testing
- Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00436709
- Testing
- bevacizumab, pegfilgrastim, cyclophosphamide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Amyloidosis
Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.
Captisol Enabled Melphalan, is a new formulation of the standard of care melphalan chemotherapy that in packaged in an inactive substance that is believed to help the chemotherapy be more stable (meaning that it doesn't lose its…
- Trial name
- NCT02909036
- Testing
- Melphalan, Pegfilgrastim, Autologous Hematopoietic Progenitor Cell Transplant
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia
This trial is a study on all-trans retinoic acid in combination with induction and consolidation therapy as well as pegfilgrastim after consolidation therapy in younger patients with newly diagnosed acute myeloid leukemia (AML).
- Trial name
- NCT00151242
- Testing
- Cytarabine, Idarubicin, Etoposide
- Where
- 34 sites in Austria, Germany
- Volunteers
- 920 people
- Sponsor
- University of Ulm
Diabetes Mellitus, Type 1, Hypoglycemia
Diabetes Islet Preservation Immune Treatment
To assess whether there is a difference in endogenous insulin secretion, measured as stimulated C-peptide secretion (area under the curve during a 4-hour mixed meal tolerance test), at the 1 year visit, for study subjects…
- Conditions
- Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases, Diabetes Mellitus
- Trial name
- DIPIT (NCT02586831)
- Testing
- Anti-Thymocyte Globulin (ATG), Interleukin 2, Exenatide
- Sponsor
- Camillo Ricordi and Jay Skyler
Locally Advanced Malignant Neoplasm, Breast Cancer
Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
This study is being conducted in patients with newly diagnosed breast cancer that will be undergoing chemotherapy prior to surgery - neoadjuvant chemotherapy.
- Trial name
- NCT01847001
- Testing
- Propranolol, DOT imaging, Paclitaxel
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Columbia University
Lymphoma
Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
- Trial name
- NCT00670358
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 138 people
- Sponsor
- Mayo Clinic